Regeneron: COVID cocktail has clear efficacy

Thursday, 25. February 2021 14:13

Regeneron Pharmaceuticals Inc. revealed on Thursday that the Independent Data Monitoring Committee (IDMC) found that its antibody cocktail treatment for non-hospitalized patients with COVID-19 shows "clear clinical efficacy." According to the company, the IDMC concluded the cocktail reduces the rate of hospitalization compared to placebo and recommended stopping enrollment into the placebo group.

Regeneron added it has not yet received the results of the IDMC research and that the data will be published in March. "In addition to the clear-cut efficacy that the IDMC has observed in this trial, it's reassuring that preclinical data from our labs and independent researchers show that REGEN-COV effectively neutralizes emerging strains of the virus, which are becoming increasingly common," said Regeneron's Chief Scientific Officer George Yancopoulos.

Related Links: Regeneron Pharmaceuticals Inc.
Breaking the News / DJ